Medivir AB (publ) (STO:MVIR)

Market Cap	1.09B +406.0%
Revenue (ttm)	9.01M +151.3%
Net Income	-90.50M
EPS	-0.39
Shares Out	617.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	940,823
Open	1.800
Previous Close	1.822
Day's Range	1.754 - 1.822
52-Week Range	0.340 - 2.885
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 13, 2026

Data Sources Report a data error